Fusion protein having the enhanced in vivo activity of erythropoietin
US8008454B2 · kind B2 · utility
33Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 10, 2001 |
| Grant date | Aug 30, 2011 |
| Priority date | — |
| Expiry date | Dec 9, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.